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MEASURING HIV ASSOCIATED MORTALITY IN AFRICA
Mortality and its predictors among antiretroviral
therapy naı¨ve HIV-infected individuals with CD4
cell count ]350 cells/mm3 compared to the
general population: data from a population-based
prospective HIV cohort in Uganda
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Background: Evidence exists that even at high CD4 counts, mortality among HIV-infected antiretroviral
therapy (ART) naı¨ve individuals is higher than that in the general population. However, many developing
countries still initiate ART at CD4 5350 cells/mm3.
Objective: To compare mortality among HIV-infected ART naı¨ve individuals with CD4 counts ]350 cells/
mm3 with mortality in the general Ugandan population and to investigate risk factors for death.
Design: Population-based prospective HIV cohort.
Methods: The study population consisted of HIV-infected people in rural southwest Uganda. Patients were
reviewed at the study clinic every 3 months. CD4 cell count was measured every 6 months. Rate ratios were
estimated using Poisson regression. Indirect methods were used to calculate standardised mortality ratios (SMRs).
Results: A total of 374 participants with CD4 ]350 cells/mm3 were followed for 1,328 person-years (PY) over
which 27 deaths occurred. Mortality rates (MRs) (per 1,000 PY) were 20.34 (95% CI: 13.9529.66) among
all participants and 16.43 (10.4825.75) among participants aged 1549 years. Mortality was higher in periods
during which participants had CD4 350499 cells/mm3 than during periods of CD4 ]500 cells/mm3 although
the difference was not statistically significant [adjusted rate ratio (aRR)1.52; 95% CI: 0.713.25]. Compared to
the general Ugandan population aged 1549 years, MRs were 123% higher among participants with CD4 ]500
cells/mm3 (SMR: 223%, 95% CI: 127393%) and 146% higher among participants with CD4 350499 cells/mm3
(246%, 117%516). After adjusting for current age, mortality was associated with increasing WHO clinical stage
(aRR comparing stage 3 or 4 and stage 1: 10.18, 95% CI: 3.8227.15) and decreasing body mass index (BMI)
(aRR comparing categories 517.4 Kg/m2 and ]18.5 Kg/m2: 6.11, 2.3016.20).
Conclusion: HIV-infected ART naı¨ve individuals with CD4 count ]350 cells/mm3 had a higher mortality than the
general population. After adjusting for age, the main predictors of mortality were WHO clinical stage and BMI.
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rural Uganda
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M
ortality among HIV-infected individuals is
much higher than in the general population
(13) with the risk of death increasing as the
CD4 cell count declines (4). Antiretroviral therapy (ART)
is currently the most effective intervention for reducing
mortality among HIV-infected individuals. The impact
of ART in reducing mortality among HIV-infected
people has been reported in developed countries (5) and
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low-income countries (6). However, in many developing
countries, ART is still initiated when there is evidence of
a significantly high risk of death, usually evidenced by
clinical deterioration or low CD4 cell count. Currently,
CD4 cell count is the most commonly used marker of
immunological deterioration and HIV disease progres-
sion (7). In 2010, the World Health Organization (WHO)
advised that HIV-infected people should be initiated on
ART when their CD4 cell count is 5350 cells/mm3 (8).
As a result Uganda responded by issuing new national
ART treatment guidelines shifting the threshold for
initiating ART from 5250 (9) to 5350 cells/mm3 (10).
Over the last decade, ART has become more readily
available with some countries even achieving universal
ART access (11). There is a debate among experts
concerning whether HIV-infected people are initiated
on ART too late (12). Evidence shows that delayed
ART initiation is associated with poorer outcomes such
as morbidity (13), and that starting ART at higher CD4
cell count reduces the risk of death (14). Besides the effect
of ART on reducing mortality and morbidity, early
initiation of ART has been reported to reduce HIV
transmission by up to 56% (15).
By providing ART only to HIV-infected people with a
low CD4 cell count, it indirectly implies that mortality
among HIV-infected individuals whose immune status is
still competent, as evidenced by higher CD4 count, is low
and similar to that observed in the general population.
However, a large observational study in Europe and
North America of over 40,000 patients reported higher
death rates among HIV-infected ART naive individuals
with CD4 cell counts ]350 cells/mm3 than among the
general population (16).
Several studies have reported predictors of mortality
among HIV-infected people but mainly among those with
advanced immunosuppression and on ART. A retro-
spective ART cohort study in Ethiopia reported weight
loss ]10%, bedridden functional status at baseline,
advanced WHO clinical stage and CD4 cell count
5200 cells/mm3 as independent predictors of death
(17). Another hospital-based ART follow-up study in
Thailand reported anaemia and severe immunosuppres-
sion at baseline as predictors of early mortality, whereas
CD4 increase from a baseline CD4 of B50 cells/mm3,
persistent anaemia and virological response at 6 months
were identified as predictors of long-term mortality (18).
On the other hand, a longitudinal pre-ART study in
Zimbabwe reported haemoglobin and HIV clinical sta-
ging (CDC classification) as strong independent predic-
tors of mortality, but this study did not assess predictors
of mortality stratified by CD4 cell count (19).
Although most HIV-associated deaths occur in sub-
Saharan Africa, information on mortality and its pre-
dictors among ART naı¨ve individuals with high CD4 cell
counts is still scarce, yet this information is useful in
informing policy on the most appropriate time to start
ART. Data on mortality patterns among HIV-infected
persons with high CD4 cell counts are essential before
expanding access to ART among this group.
We conducted the current study among HIV-infected
ART naı¨ve individuals with CD4 cell count ]350 cells/
mm3. We estimated overall mortality, compared mortality
in the CD4 cell count category 350499 cells/mm3 with
that in the ]500 cells/mm3 category, and compared
mortality among study participants with mortality in the
general population in Uganda. We also investigated risk
factors for death among HIV-infected ART naı¨ve persons
with CD4 cell count ]350 cells/mm3.
Methods
Setting and study population
The Rural Clinical Cohort (RCC) is an open HIV cohort
that followed a total of 696 HIV-positive participants
between 1992 and 2011. It is located in rural southwest
Uganda and was established to study the natural history
of HIV infection. The study setting has a stable, homo-
geneous population with most people belonging to the
Baganda tribe. The majority of people are Christians and
half the population is below 15 years of age (20). The
RCC is nested within a large general population cohort
(GPC) that conducts annual serosurveys and census on
20,000 residents of 25 study villages (2123). In 1990, the
RCC recruited one third of the HIV prevalent cases
identified in the 1989 baseline GPC serosurvey; there-
after, HIV incident cases identified in subsequent annual
GPC serosurveys were recruited (24). Following ART
availability in Uganda in 2004, HIV-positive cases that
remained in the GPC were invited to be screened and
were enrolled into RCC if they qualified to start ART.
Study participants’ recruitment and follow-up
Trained field workers visited individuals eligible for
enrolment, explained the nature of the study and invited
them to the study clinic where they gave informed consent
before enrolment. After enrolment, study participants
attended scheduled visits every 3 months at the study
clinic. Data collected included medical, demographic,
sexual and behavioural history and WHO clinical stage.
HIV infection was staged according to WHO clinical
staging (25). The WHO clinical staging system was
developed in 1990 to guide physicians, in resource-limited
settings, to make decisions related to management of
HIV/AIDS patients. According to the WHO clinical
staging system, HIV disease progression is grouped into
four stages, i.e. stages 1, 2, 3 and 4. Study participants
attended interim visits whenever ill and they received free
investigations and treatment according to national guide-
lines (26) or were referred to a nearby health facility
about 20 km away, for in-patient management. In 2004,
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ART was introduced for all eligible HIV-infected indivi-
duals according to the existing National ART guide-
lines at the time (27). These guidelines described ART
eligibility then as: CD4 count of 200 cells/mm3 or below,
or WHO clinical stage 4, or advanced stage 3 with
persistent or recurrent oral thrush and invasive bacterial
infections regardless of CD4 count, or CD4 count of 250
cells/mm3 or below in pregnancy. Although the National
Cotrimoxazole prophylaxis guidelines were released in
2005 (28), cotrimoxazole prophylaxis among HIV-
infected individuals had been introduced in the cohort
in 2004. To minimize loss to follow-up, study participants
were transported to the study clinic (or given transport
refund) for their scheduled visits, and those who missed
their scheduled visits were visited at home within 3 days.
Field workers who received information about a study
participant’s death by the deceased’s next of kin, relative,
friend or community-based recorders in the GPC notified
study clinicians of deaths.
Laboratory assessment
CD4 cell counts were measured every 6 months among
HIV-infected study participants not yet on ART, using
FACS Count Machine (Becton Dickinson, San Jose,
California, USA). HIV viral load measurement was
done at enrolment and annually thereafter, using two
methods during the study. Up to September 2007, we
used the VERSANT RNA 3.0 (Bayer, Bayer HealthCare,
NY, USA) assay (lower detection limit50 copies/ml).
However, due to problems with lack of reagents and lack
of service support, we used the COBAS Amplicor
MONITOR 1.5 (Roche, Roche Molecular Systems, NJ,
USA) assay (lower detection limit400 copies/ml) from
October 2007 onwards. Other laboratory tests done at
scheduled visits included thick blood malaria smears,
stool analysis, urine examination and full blood counts.
Outcome
The outcome of interest was death, with mortality rates
(MRs) estimated from deaths per 1,000 person-years
(PY), and age- and sex- standardised MRs.
Exposures
The primary exposure variable was current CD4 count
350499 and ]500 cells/mm3 among ART naı¨ve HIV-
infected individuals. The following secondary exposure
variables were measured at enrolment: age, sex, tobacco
consumption (measured as years of tobacco consumption
and number of times tobacco is consumed each day),
alcohol consumption (measured as number of units
consumed and number of consumption days each
week), level of education (none, primary and secondary
or above) and height (in centimetres). The following
secondary exposure variables were measured at enrol-
ment and every 3 months: marital status (married, with
steady sexual partner, single, divorced or widowed),
diarrhoea (three or more loose motions each day) for
more than 1 month, WHO clinical stage (measured as
stage 1, 2, 3 or 4), malaria (diagnosed from blood smear),
height, weight (in kilograms) and viral load.
Statistical analysis
Data were double-entered, cleaned and validated using a
MS Access database and analysed using STATA version
11.0 (StataCorp, College Station, Texas, USA). Mortality
data from the general Ugandan population were ex-
tracted from the 2011 Uganda Demographic and Health
Survey (DHS) (29). At the time of the DHS, there were a
total of 80 districts from which a representative sample of
9,854 households was selected using multistage sampling.
Age-specific MRs, for women and men aged 1549 years,
were calculated for the 7 years before the survey was
carried out (mid-2004 to mid-2011).
Because our primary objective was to estimate mor-
tality among HIV-positive persons who were not yet
eligible for ART, person-time at risk started at the first
CD4 cell count ]350 cells/mm3 and was censored at the
earliest of death, CD4 cell count B350 cells/mm3, start of
ART or date last seen. Multiple episodes of observation
and gaps were allowed if an individual’s CD4 count fell
below 350 and then later increased to ]350 cells/mm3
without ART initiation. Loss to follow-up was defined as
a participant who was not known to be dead but had not
been seen at the study clinic for at least 1 year. If a
participant missed a CD4 cell count at a scheduled visit,
the value from the previous visit was carried forward,
if within the last 6 months. CD4 cell counts were con-
sidered to be unknown during periods when there was
6 months since the last CD4 cell count and this period
was excluded from the analysis. Similarly, viral load data
were carried forward if the previous measurement was
less than 12 months ago. Viral load measurements were
considered to be unknown in the periods when there was
12 months since the last measurement.
Baseline characteristics (defined as the point when the
participant first entered the analysis) were calculated and
tabulated by CD4 count category. Calendar time was
divided into two periods before ARTwas available (1992
1999 and 20002003) and two periods after ART was
available (20042007 and 20082011). MRs were calcu-
lated using standard person-year methods. Crude and
adjusted rate ratios (RR) were calculated using Poisson
regression and associations assessed using likelihood
ratio tests (LRT). Adjusted RRs (aRR) for CD4 count
category, adjusted for the effect of current age, sex and
calendar period as a priori confounders, were calculated.
Effect modification of CD4 cell count category by age,
sex and calendar period was also assessed.
To identify independent risk factors for mortality, a
multivariate Poisson model was constructed. Current age
was considered to be a priori confounder and included in
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all models. Variables that were measured at each visit were
analysed as time-updated exposures. Risk factors thatwere
associated with mortality at PB0.20 in the univariate
analysis were assessed for inclusion in the multivariate
model. A forward stepwise methodwas used, starting with
the factor that had the strongest association and adding
other factors to the model one by one; those that were
associated at PB0.05 were retained. In the final model,
effect modification between CD4 count category and each
of the other covariates was assessed. Survival probabilities
were evaluated using Kaplan-Meier curves stratified by
CD4 count categories. Standardised mortality ratios
(SMRs) for age and sex were calculated using the indirect
method and the analysis was restricted to 1549 years of
age tomatchwith theUgandaDHSdata.With the indirect
method of standardisation, the age- and sex-specific MRs
in the Ugandan population are multiplied by the person-
years in each sex and age group in our study cohort to
obtain the expected number of deaths in our cohort if the
two populations had the same mortality.
Ethical considerations
The RCC from which this data was extracted received
ethical approval from theUgandaVirus Research Institute
Science and Ethics committee and the Uganda National
Council for Science and Technology. All informed consent
and confidentiality procedures were adhered to.
Results
Characteristics of participants
Between June 1992 and March 2011, 374 participants
had a CD4 cell count ]350 cells/mm3 on at least one
occasion during follow-up (Table 1). Overall median
age among study participants was 31 years (IQR: 25
41), and 55% (n204) were females. At baseline, defined
as entry to the analysis, 71% (n264) of participants had
a CD4 cell count ]500 cells/mm3, and 29% had a CD4
cell count of 350499 cells/mm3. The majority (n243,
65%) of participants were married or had a steady sexual
partner, and had some primary education (66%). Most
participants (65%) reported not using tobacco and not
consuming alcohol (69%). Sixteen percent of participants
had a body mass index (BMI) B18.5 Kg/m2, 8% had
haemoglobin level of B11 g/dL, and 3.2% were in WHO
clinical stage 3 or 4. There were no significant differences
in the distribution of the baseline characteristics by CD4
cell count category.
Missing data
At baseline, only a small proportion of participants
(B10%) had missing data for most covariates, except
for haemoglobin that was missing for 23% participants
(Table 1). During follow-up, CD4 counts were missing
in 15% of the total observation time, and viral load
measurements were missing during 31% of observation
time. Other covariates were missing for B2% of observa-
tion time, except for haemoglobin which was missing for
9% of observation time.
Follow-up time and survival among participants
with CD4 ]350 cells per mm3
Thirteen (3.5%) participants were censored due to loss to
follow-up, of whom 11 (85%) had a CD4 cell count ]500
cells/mm3 and two (15%) had a CD4 cell count 350499
cells/mm3. Overall, the 374 participants in the periods
with CD4 cell count ]350 cells/mm3 contributed 1,328
PY at risk. There were 2,921 visits made by 295 par-
ticipants during periods of CD4 count 350499 cells/
mm3; 60% (n1,766) of visits were scheduled follow-
up visits and the remainder were interim (unscheduled)
visits. At 43 scheduled visits (2.4%), participants reported
having been hospitalised since their last visit; overall,
34 participants (11.5%) were hospitalised at least once
during a period when their CD4 count was 350499 cells/
mm3. There were 5,521 visits made by 309 participants
during periods of CD4 counts ]500 cells/mm3; 64%
(n3,551) of visits were scheduled follow-up visits.
Participants reported having been hospitalised at 66
scheduled visits (1.9%); overall, 48 participants (15.5%)
were hospitalised at least once when their CD4 count was
]500 cells/mm3.
There were 27 deaths among the study participants
(overall MR20.34/1,000 PY; 95% CI: 13.9529.66).
Twelve deaths occurred among individuals with CD4 cell
count 350499 (MR27.10/1,000 PY; 95% CI: 15.37
47.66) and 15 deaths among individuals with CD4 count
]500 (MR17.00/1,000 PY; 95% CI: 10.2328.14)
(Table 4). Twelve deaths (MR17.20/1,000 PY; 95%
CI: 9.7730.29) occurred in the pre-ART period (1990
2003) and 15 deaths (MR23.80/1,000 PY; 95% CI:
14.3539.48) occurred in the ART period (20042011)
(Data not shown).
Although not statistically significant, the unadjusted
MR in participants with CD4 cell count 350499 cells/
mm3 was 1.6 times higher than in those with CD4 cell
count ]500 cells/mm3 (Table 2 and Fig. 1). After
adjusting for age, sex and calendar period, the risk of
death among those with CD4 cell count 350499 cells/
mm3 remained higher than among those with CD4 cell
count ]500 cells/mm3, but the difference was still not
statistically significant (aRR:1.44; 95% CI: 0.713.25)
(Table 2). There was some evidence that the effect of
CD4 cell count category varied by calendar period. Par-
ticipants with CD4 cell count category 350499 cells/
mm3 had a higher MR than those with CD4 cell count
]500 cells/mm3 in the period before 2004, however,
after 2004, the MR in participants with CD4 cell count
350499 cells/mm3 was lower than that that in partici-
pants with CD4 cell counts ]500 cells/mm3 (P-value for
Ben Masiira et al.
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Table 1. Distribution of characteristics at study entry by CD4 cell count category
CD4 cell count (cells/mm3) N374
Characteristic 350499 n110 (column %) ]500 n264 (column %) Total (column %)
Age (years) P0.49
1419 9 (8.2) 22 (8.3) 31 (8.3)
2029 33 (30.0) 103 (39.0) 136 (36.4)
3039 33 (30.0) 70 (26.5) 103 (27.5)
4049 22 (20.0) 39 (14.8) 61 (16.3)
]50 13 (11.8) 30 (11.4) 43 (11.5)
Overall median age (IQR) 32 (2543) 30 (2440) 31 (2541)
Sex P0.11
Female 53 (48.2) 151 (57.2) 204 (54.5)
Male 57 (51.8) 113 (42.8) 170 (45.5)
Tribe P0.12
Baganda 57 (51.8) 162 (61.4) 219 (58.6)
Banyarwanda 28 (25.5) 59 (22.3) 87 (23.3)
Other 17 (15.5) 36 (13.6) 53 (14.2)
Missing 8 (7.3) 7 (2.7) 15 (4.0)
Religion P0.07
Catholic 61 (55.5) 170 (64.4) 231 (61.8)
Church of Uganda 24 (21.8) 37 (14.0) 61 (16.3)
Other 18 (16.4) 50 (18.9) 68 (18.2)
Missing 7 (6.4) 7 (2.7) 14 (3.7)
Marital status P0.88
Married /Steady sexual partner 73 (66.4) 170 (64.4) 243 (65.0)
Single 9 (8.2) 25 (9.5) 34 (9.1)
Divorced/widowed 27 (24.5) 64 (24.2) 91 (24.3)
Missing 1 (0.9) 5 (1.9) 6 (1.6)
Education level P0.47
None 14 (12.7) 43 (16.3) 57 (15.2)
Primary 72 (65.5) 175 (66.3) 247 (66.0)
Secondary and above 18 (16.4) 39 (14.8) 57 (15.2)
Missing 6 (5.5) 7 (2.7) 13 (3.5)
Alcohol consumption (times/week) P0.14
Don’t use 69 (62.7) 190 (72.0) 259 (69.3)
13 30 (27.3) 59 (22.4) 89 (23.8)
]4 10 (9.1) 15 (5.7) 25 (6.7)
Missing 1 (0.9) 0 1 (0.3)
Years of tobacco use P0.79
Don’t use 70 (63.6) 172 (65.2) 242 (64.7)
55 10 (9.1) 31 (11.7) 41 (11.0)
610 7 (6.4) 14 (5.3) 21 (5.6)
1119 12 (10.9) 21 (8.0) 33 (8.8)
]20 4 (3.6) 14 (5.3) 18 (4.8)
Missing 7 (6.4) 12 (4.5) 19 (5.1)
Body mass index (Kg/m2) P0.46
]25.0 5 (4.5) 21 (8.0) 26 (7.0)
18.5B25 83 (75.5) 201 (76.1) 284 (75.9)
B18.5 20 (18.2) 40 (15.2) 60 (16.0)
Missing 2 (1.8) 2 (0.8) 4 (1.1)
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interaction0.02). There was no evidence of effect modi-
fication by age (P0.38) or sex (P0.97).
Mortality in participants with CD4 ]350 cells per
mm3 compared with the general population
Among individuals aged 1549 years, the MR in the
Ugandan population was 5.66/1,000 PY (95% CI: 5.46
5.87), compared with 16.43/1000 PY (95% CI: 10.48
25.75) among study participants with CD4 count ]350
cells/mm3. Mortality was 146% higher among study
participants with CD4 counts of 350499 cells/mm3
(SMR246%; 95% CI: 117516%) and 123% higher
among study participants with CD4 counts of ]500
cells/mm3 (SMR: 223%; 95% CI: 127393%). Mortality
in male participants with CD4 ]350 cells/mm3 was more
than double that in males in the general Ugandan
population (SMR: 313%; 95% CI: 173565%). Mortality
in female participants with CD4 ]350 cells/mm3 was
over 100% higher than that in females in the general
Ugandan population (SMR: 245%; 95% CI: 123490%;
Table 3).
Risk factors for mortality among participants
with CD4 ]350 cells/mm3
In the univariate analysis, mortality was strongly asso-
ciated with increasing current age (RR2.8; 95% CI:
1.17.5 comparing those aged ]50 years with those
3039 years; P0.001) and decreasing BMI (RR17.1;
95% CI: 7.041.8, comparing BMI B17.5 Kg/m2 with
BMI ]18.5 Kg/m2; PB0.001). Mortality was also
strongly associated with a haemoglobin level B11 g/dL
(RR3.8; 95% CI1.68.8; P0.005) and increasing
WHO clinical stage (17.9; 95% CI: 7.443.3, comparing
WHO stage 3 or 4 and WHO stage 1; PB0.001). There
was also an association between mortality and increasing
viral load (RR4.4; 95% CI: 1.118.5, comparing viral
load categories ]250,000 copies/ml and B25,000 copies/
ml; P0.003).
In the multivariate analysis, after adjusting for current
age, independent factors associated with mortality were
decreasing BMI (aRR6.1; 95% CI: 2.316.2, compar-
ing BMI B17.5 kg/m2 to BMI ]18.5 kg/m2; PB0.001)
and increasing WHO clinical stage (aRR10.2, 95% CI:
3.827.2 comparing WHO stage 3 or 4 to WHO stage 1;
PB0.001) (Table 4). After adjusting for current age, BMI
and WHO stage, although mortality was slightly higher
in those with CD4 cell count 350499, there was no
evidence of an association with CD4 count category
(aRR1.2, 95% CI; 0.62.7; P0.63). There was no
evidence of effect modification of CD4 count category by
any of the covariates in the final model (P-value for
interaction with age0.42, with BMI0.77 and with
WHO stage0.36).
Table 1 (Continued )
CD4 cell count (cells/mm3) N374
Characteristic 350499 n110 (column %) ]500 n264 (column %) Total (column %)
Haemoglobin (g/dL) P0.70
B11.0 9 (8.2) 21 (8.0) 30 (8.0)
] 11.0 76 (69.1) 172 (65.2) 248 (66.3)
Missing 25 (22.7) 71 (26.9) 96 (25.7)
WHO stage P0.64
1 91 (82.7) 215 (81.4) 306 (81.8)
2 13 (11.8) 29 (11.0) 42 (11.2)
3 and 4 4 (3.6) 8 (3.0) 12 (3.2)
Missing 2 (1.8) 12 (4.5) 14 (3.7)
P-value from Chi-squared test for comparison of proportions.
Table 2. Crude rate ratios and rate ratios adjusted for current age, sex and time period, by CD4 cell count category
CD4 category
(cells/mm3)
Deaths
(person-years)
Mortality rate/1,000
person-years (95% CI)
Crude rate
ratio (95% CI)
Adjusted rate
ratio (95% CI)
P0.23$ P0.29$
]500 15 (884) 17.00 (10.2328.14) 1.00 1.00
350499 12 (443) 27.07 (15.3747.66) 1.60 (0.753.41) 1.52 (0.713.25)
95% CI95% confidence interval.
$P-value from likelihood ratio test.
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Discussion
In this study, we found that mortality among individuals
with CD4 cell count 350499 cells/mm3 was higher than
that among people with CD4 ]500 cells/mm3, although
this was not statistically significant. Individuals with CD4
cell count 350499 cells/mm3 and ]500 cells/mm3 had
146% and 123% higher risk of death compared with the
general population of Uganda. After adjusting for age,
increasing WHO clinical stage and decreasing BMI were
independent predictors of death.
Among the strengths of this study was the prospective
study design, which allowed measurement of the main
exposure of interest (CD4 cell count), and other time-
varying exposures. There was active tracing of partici-
pants who missed their scheduled visits which ensured
good compliance, minimized loss to follow-up and re-
duced number of missed deaths. Participant recruitment
was done from a general population source which min-
imized selection bias and made study findings more
representative of the population. The long study duration
Fig. 1. Kaplan-Meier survival function for cohort, by CD4 cell count category.a
aP-value for log-rank test for equality of survival function0.14.
Table 3. Standardised mortality ratios (SMRs), by sex, among individuals 549 years and CD4 cell count ]350 cells/mm3
Observed
cohort deaths
Observed follow-
up (person-years)
Mortality rate in standard
population (per 1,000 person-years)
Expected
deaths SMR (95% CI)
Age (]500 cells/mm3)
1529 years 1 325 3.5 1.14
3039 years 4 300 8.2 2.46
4049 years 7 150 11.9 1.79
Overall 12 775 5.7 5.39 223% (127393%)
Age (350499 cells/mm3)
1529 years 1 119 3.5 0.42
3039 years 4 178 8.2 1.46
4049 years 2 81 11.9 0.96
Overall 7 378 5.7 2.84 246% (117516%)
Males
]500 cells/mm3 6 353 2.29
350499 cells/mm3 5 188 1.22
Overall 11 541 6.5 3.51 313% (173565)
Females
]500 cells/mm3 6 422 2.24
350499 cells/mm3 2 194 1.03
Overall 8 616 3.27 245% (123490%)
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Table 4. Univariate and multivariate analysis of factors associated with death among individuals with CD4 ]350
cells/mm3
Variable
Deaths
(person-years)
Mortality rate
(per 1,000 person-years)
Crude rate ratio
(95% CI)
Adjusted rate ratio%
(95% CI)
Current age (years) P0.001$ P0.16$
1429 2 (446) 4.5 0.27 (0.061.27) 0.41 (0.091.96)
3039 8 (480) 16.7 1.00 1.00
4049 9 (231) 39.0 2.34 (0.906.05) 1.81 (0.694.72)
]50 8 (171) 46.8 2.81 (1.057.48) 1.61 (0.584.50)
Sex P0.23$ P0.85$
Female 11 (693) 15.9 1.00 1.00
Male 16 (635) 25.2 1.59 (0.743.42) 1.08 (0.482.45)
Marital status* P0.10$ P0.09$
Married 13 (885) 14.7 1.00 1.00
Single 2 (120) 16.7 1.14 (0.265.04) 1.18 (0.265.49)
Widowed/Divorced 11 (307) 35.8 2.44 (1.095.44) 3.21 (0.6416.16)
Alcohol consumption P0.37$ P0.11$
Yes 18 (986) 18.3 1.00 1.00
No 9 (340) 26.4 1.45 (0.653.22) 2.07 (0.874.96)
Tobacco use* P0.08$ P0.90$
No 11 (884) 12.4 1.00 1.00
Yes 11 (417) 26.4 2.12 (0.924.89) 0.94 (0.372.40)
Body mass index (Kg/m2)* PB0.001$ PB0.001$
]18.5 8 (1,101) 7.3 1.00 1.00
17.5B18.5 6 (121) 49.8 6.85 (2.3819.73) 4.52 (1.5413.32)
B17.5 12 (97) 124.3 17.10 (6.9941.84) 6.11 (2.3016.20)
Haemoglobin (g/dL)* P0.005$ P0.09$
]11.0 17 (1,100) 15.8 1.00 1.00
B11 8 (134) 59.7 3.78 (1.638.76) 0.43 (0.171.07)
CD4 category P0.23$ P0.65$
]500 cells/mm3 15 (884) 17.0 1.00 1.00
350499 cells/mm3 12 (443) 27.1 1.60 (0.753.41) 1.22 (0.562.67)
WHO stage PB0.001$ PB0.001$
1 8 (987) 8.1 1.00 1.00
2 6 (241) 24.9 3.07 (1.078.85) 2.36 (0.777.19)
3 and 4 13 (89) 145.5 17.94 (7.4443.29) 10.18 (3.8227.15)
Malaria during follow-up* P0.44$ P0.81$
No 23 (1,151) 20.0 1.00 1.00
Yes 2 (169) 11.8 0.59 (0.142.51) 0.84 (0.203.61)
Diarrhoea1 month P0.18$ P0.48$
No 26 (1,319) 19.7 1.00 1.00
Yes 1 (9) 112.1 5.69 (0.7741.90) 2.26 (0.2917.41)
Viral load (copies/ml)* P0.03$ P0.45$
B25,000 5 (467) 10.7 1.00 1.00
25,000B100,000 4 (268) 14.9 1.39 (0.375.20) 0.92 (0.243.47)
100,000B250,000 6 (114) 52.5 4.90 (1.4916.05) 2.37 (0.698.17)
]250,000 3 (64) 47.2 4.41 (1.0518.45) 1.67 (0.357.00)
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enabled us to accrue a reasonable number of person-years
of observation.
However, the study limitations included the small
numbers of deaths which makes mortality estimates from
our study subject to substantial reduction in statistical
power. The study lacked information on the duration of
HIV infection for participants who had been recruited as
prevalent cases. Since disease duration is a key factor
known to influence mortality among HIV-infected indivi-
duals, survival bias could not be excluded. The analysis
did not take into account of the confounding effect of
tuberculosis which is prevalent in the study area and a
major cause of death. Some of the time-varying variables
such as smoking and education were not recorded during
follow-up. The big proportion ofobservation time inwhich
some exposure variables such as CD4 cell count (the main
exposure of interest) and viral load were missing had an
impact statistical power. Lastly, there was no adjustment
made for cotrimoxazole prophylaxis on the individual level
since these data were not available; however, we did adjust
for calendar period which would have captured some
of this effect, since cotrimoxazole was prescribed for all
patients after 2004.
Although not significant due to small numbers, the
higher mortality among individuals with CD4 cell count
350499 cells/mm3 compared with CD4 cell count ]500
cells/mm3 is an indication of the increased riskof mortality
associated with deteriorating immune status which has
been reported in previous studies (30, 31). Our reported
MRs in the CD4 categories of 350499 and ]500 cells/
mm3 (17.0 and 27.1 per 1,000 PY, respectively) are similar
to what has been reported in a pre-ART follow-up study
done in Ivory Coast (32). However, our observed MRs
are lower than what was reported in a pre-ART study in
West Africa (33). The latter was a bigger study based on
data from five longitudinal cohorts. However, that study
did not have data from a reference population to enable the
calculation of SMRs to compare observed mortality with
background population mortality.
Individuals who are on ART and have achieved high
CD4 cell count have been reported to have a similar
mortality experience to that of the general population (34).
Therefore, onewould expect a similar mortality experience
among HIV-infected ART naı¨ve individuals with compar-
able immune status. However, our results indicate that
people with CD4 cell count ]350 cells/mm3 have a higher
risk of death than that in the general population of
Uganda. A study in France also reported a higher overall
mortality among individuals on combinational ART than
in the general population. However, among individuals
who had attained CD4 cell counts ]500 cells/mm3, the
mortality which was higher than that in the general
population up to 3 years on ART reached the level in the
general population after the sixth year on ART (35). In
reality, not offering ART to people with CD4 cell count
]350 cells/mm3 is mainly due to cost implications and
concerns about long-term potential side effects, but it may
also indirectly imply that the risk of death among this
group of individuals is low. In our cohort, where partici-
pants were regularly reviewed by study clinicians and
received free medical care, one would expect mortality to
be similar to that seen in the general population of
Uganda. There is evidence that participants in cohorts
with free access to investigations and treatment are less
likely to die (32) and therefore mortality estimates from
our cohort are likely to underestimate mortality of HIV-
positive individuals in Uganda in general.
Our results raise three important questions for physi-
cians and policy makers in the developing countries
where the threshold for starting ART is 5350 cells per
mm3: 1) Are we still waiting too long to start HIV-
infected individuals on ART? 2) Are we actually treating
all individuals who need ART? 3) Is it still necessary to
start people on ART basing on CD4 cell count cut-offs?
Table 4 (Continued )
Variable
Deaths
(person-years)
Mortality rate
(per 1,000 person-years)
Crude rate ratio
(95% CI)
Adjusted rate ratio%
(95% CI)
Calendar period P0.67$ P0.27$
19921999 5 (381) 13.1 1.00 1.00
20002003 7 (315) 12.2 1.69 (0.545.33) 1.60 (0.505.11)
20042007 8 (350) 22.8 1.74 (0.575.32) 1.82 (0.575.78)
20082011 7 (281) 24.9 1.90 (0.606.00) 3.22 (0.9910.39)
*Variables with some missing data. For all variables except haemoglobin and viral load, data are missing for B2% of total observation
time. Haemoglobin missing for 8.8% of observation time (117 PY) and viral load missing for 31.3% (415 PY).
$P-value from likelihood ratio test.
%Adjusted for age (a priori) and all independent predictors of mortality (variables in bold): age, BMI and WHO stage. The final model was
based on 1,308 PY of observation time and 26 deaths.
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The above questions have to be answered in the context
of available evidence and the economical implications of
starting ART at higher CD4 cell counts in the developing
world.
Although this study is based on small numbers, it
supplements the existing evidence that mortality among
HIV-infected people with high CD4 cell count is higher
than that in the general population. More light will be
shed from results of an ongoing multi-site randomized
START Trial that is assessing whether immediate initia-
tion of ART at CD4 cell counts above 500 cells/mm3 is
superior to deferral of ART until CD4 cell count declines
below 350 cells/mm3 (36). Nevertheless, long-term bene-
fits of ART, especially in reducing HIV-associated
mortality and morbidity and reducing HIV transmission,
clearly outweigh the cost implications which are often
cited in sub-Saharan Africa.
Increasing WHO clinical stage and decreasing BMI
were identified as predictors of death among individuals
with CD4 cell count above ]350 cells/mm3. WHO
clinical stage and BMI could both reflect underlying
morbidity such as tuberculosis which is common among
HIV-infected persons in sub-Saharan Africa and is a
major cause of death. Low BMI can also reflect other
conditions like malnutrition and HIV wasting syndrome
which are associated with HIV infection and are well
known to lead to poor survival. These findings further
confirm the importance of WHO clinical stage assess-
ment in HIV care, especially in this era when CD4 cell
count is increasingly becoming available to clinicians.
Conclusion
This study provides additional evidence that mortality
among HIV-infected ART naı¨ve individuals with CD4
cell count ]350 cells per mm3 is higher than that in the
general population. To avert these preventable deaths,
ART guidelines in developing countries should aim to
initiate ART at higher CD4 cell counts than the current
threshold, as is done in developed countries. Conse-
quently, there is a need to allocate more resources for the
expected increase in patients initiating ART at the higher
CD4 threshold. After adjusting for current age, WHO
clinical stage and BMI were the main predictors of
mortality, and they should be considered during the
clinical assessment for ART eligibility.
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